| Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
|---|
| Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
|---|
| Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
|---|
Leidos Holdings, Inc (NYSE:LDOS) reported second-quarter fiscal 2024 revenue growth of 8% year-over-year to $4.13 billion, beating the analyst consensus estimate of $4.06 billion, driven by demand across all customer segments, especially for managed health services.
The defense, aviation, information technology, and biomedical research company’s adjusted EPS was $2.63, up 46% year over year, beating the analyst consensus estimate of $2.27.
Adjusted net income was $358 million for the quarter, up 43.8% year-over-year.
Adjusted EBITDA was $559 million, up 33% year over year. The margin of 13.5% increased from 10.9% a year ago.
Net bookings totaled $4.0 billion for the quarter, representing a book-to-bill ratio of 1.0. As a result, the backlog at the end of the year was $36.5 billion, of which $8.0 billion was funded.
Leidos held $823 million in cash and equivalents as of June 28, 2024.
CEO Thomas Bell commented, “Our collaborative innovation strategy and capabilities-based organization position us well to deliver on our commitments for the remainder of 2024 and beyond.”
Outlook: Leidos expects fiscal 2024 revenue of $16.1 billion-$16.4 billion (prior $16.0 billion – $16.4 billion). The analyst consensus stands at $16.25 billion.
The company expects its fiscal 2024 adjusted EPS of $8.60 – $9.00 (prior $8.40 – $8.80) versus the $8.82 consensus.
Leidos Holdings stock gained 64% in the last 12 months.
Price Action: LDOS shares are trading lower by 3.29% at $147.93 at the last check on Tuesday.
Posted In: LDOS
